Rexahn Pharmaceuticals announces new data for Supinoxin showing potent tumour growth inhibition

Dr Fuller-Pace commented: "The accumulating data for Supinoxin suggest that it targets a unique protein that may play a prominent role in an important biological pathway that leads to the growth and metastasis of cancerous cells and therefore is a promising new potential anti-cancer therapeutic. The current survival and tumour inhibition data in the TNBC model are particularly intriguing as this patient population represents a subset of breast cancer patients with high unmet medical need. We look forward to continuing to build on this promising body of data."

"We are very pleased to see potent tumour inhibition effects in a well validated preclinical model following oral administration of Supinoxin," said Dr Ely Benaim, Chief Medical Officer for Rexahn. "Supinoxin is currently being evaluated in an ongoing Phase I multi-center, dose-finding, open-label, single agent clinical study in patients with advanced or metastatic solid tumours. Recently presented data from the Phase I trial showed promising preliminary evidence of clinical activity. We look forward to additional data from this study."